The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)
Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies.
The Genetics or Epigenetics of Substance Use Disorders Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction. These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction. Investigators outside the field of addiction interested in applying their novel approaches to the genetics or epigenetics of addiction are encouraged to apply. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics of substance use disorders.
- Letter of Intent Due Date(s): 30 days before application due date
- Application Due Date(s): October 19, 2020, October 19, 2021, October 19, 2022
PAR-20-225 Expiration Date October 20, 2022
For the purpose of this FOA, multiple PD(s)/PI(s) are not allowed. The Project Director/Principal Investigator (PD/PI) is the only individual who can be listed on the SF424 form.
Applicants must meet the definition of an Early Stage Investigator (ESI) at the time of submission. An ESI is a new investigator (defined as a PD/PI who has not completed successfully for a significant NIH independent research award) who is within 10 years of completing his/her terminal research degree or is within 10 years of completing medical residency (or the equivalent). A complete list of NIH grants that do not disqualify a PD/PI as a new investigator can be found at: https://grants.nih.gov/policy/early-investigators/index.htm.
Frequently Asked Questions about the NIH Early Stage Investigator (ESI) Policy can be found at https://grants.nih.gov/policy/early-investigators/index.htm/.
An extension to the 10-year period may be granted under special circumstances (e.g., childbirth, family care responsibilities, extended periods of clinical training, disability or illness, etc.). See NOT-OD-19-125 (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-19-125.html) for instructions on applying for an ESI extension.
Applicants are responsible for reviewing and/or updating their degree information in their eRA Commons account in a timely fashion. Applicants should allow several weeks for an extension request to be processed. NOTE: If an applicant is not identified as an ESI in the eRA Commons, it may result in the application not being reviewed.
Applicants also must hold an independent research position at a domestic (U.S.) institution as of September 1 of the fiscal year of the competition (Federal Fiscal Year starts October 1 and ends September 30). For the purpose of this FOA, “independent research position” means a position that automatically confers eligibility, by the applicant’s institutional policy, for an investigator to apply for R01 grants, with an appropriate commitment of facilities to be used for the conduct of the proposed research. Investigators still in training or mentored status (postdoctoral fellows) may apply if, by the receipt date, they have a written commitment of an independent faculty position as of September 1 of the fiscal year of the competition.
Applicants may submit or have an R01 (or other equivalent) grant application pending concurrently with their Avenir Award application provided that each application is scientifically distinct. If the applicant receives an R01 before the Avenir can be awarded, then the investigator is no longer eligible for an Avenir award. Please see section 3, below, for more information about limitations on overlapping applications.
Awardees are required to commit at 3 person months (25%) out of a 12 month calendar year each year to activities supported by the Avenir Award.
Application budgets are limited to $300,000 in Direct Costs each year for up to five years, plus applicable Facilities and Administrative (F&A) costs to be determined at the time of award.